Keyword: Novartis

Novartis has reupped with Recro Pharma's CMO for production of two drugs, plus other news.

Vas Narasimhan’s 2018 take-home pay suffered on bottom-of-the-barrel shareholder returns over three years, compared with its Big Pharma rivals.

A new study suggests that the consistency of payments from drugmakers to doctors matters the most when it comes to swaying prescribing habits.

Sweep out drug rebates for patient discounts instead? Supply chain players hate the idea, but Big Pharma CEOs are all over it.

The Sandoz manufacturing network will be further 'optimized' as Novartis turns Sandoz into an autonomous unit in the next 18 months.

Payer coverage is key to Novartis’ plan to get Kymriah going, and the company is going to be getting some more of that.

Two senators have introduced a bill designed to encourage deals that would allow insurers to spread payments for expensive therapies over time.

Despite new competition from CGRP migraine prevention drugs, Allergan executives contend Botox can continue to grow.

It's been a long slog through a sluggish launch, but Novartis' highly anticipated heart drug Entresto has finally reached blockbuster status.

Novartis figures biopharma companies both large and small will need to embrace alternative payment models for pricey gene and cell therapies.